Will Gilead's Hepatitis C Dominance Collapse?
The launch of two multibillion-dollar blockbuster HCV drugs in the past year and a half has firmly established Gilead Sciences (NASDAQ: GILD) as a Goliath in hepatitis C treatment. However, Johnson & Johnson (NYSE: JNJ) has recently orchestrated deals ...
Investopedia - Thu, 28 May 2015 11:11

Gilead's Sustainable Competitive Advantage
Motley Fool - Thu, 28 May 2015 08:58

Gilead Sciences Is Still Undervalued (GILD)
Seeking Alpha - Thu, 28 May 2015 10:44

Gilead Will Hire Up to 170 Scientists in $100 Million Edmonton Expansion
PharmaLive (press release) (subscription) - Fri, 29 May 2015 06:41

Lamphier: Gilead announces $100-million manufacturing plant
Edmonton Journal - Wed, 27 May 2015 19:48

Gilead cuts ribbon on innovative new laboratory, announces additional $100m ...
CNNMoney - Wed, 27 May 2015 13:37

Consumers Sue Anthem for Denying Coverage for a Gilead Hepatitis C Drug
The controversy over the new crop of hepatitis C treatments has taken yet another turn as consumers are starting to file lawsuits against insurers that deny them access to the medicines. Over the past two weeks, two different women alleged that Anthem ...
Wall Street Journal (blog) - Tue, 26 May 2015 07:20

Hepatitis C: Cost in the way of a cure
New Pittsburgh Courier - Tue, 26 May 2015 12:30

Should This Figure Worry Gilead Shareholders?
Investopedia - Tue, 26 May 2015 08:56

Police: Robber threatened guard with dirty syringe, Hepatitis C
When a security guard stopped Eaton in the parking lot, Eaton mentioned there was a syringe in his pocket and that he might have Hepatitis C. He then fled. Police posted a picture of the two men the next day on the department's Facebook page, the ...
Q13 FOX - Thu, 28 May 2015 06:41

Police: Robber arrested after threatening guard with syringe
KXLY Spokane - Thu, 28 May 2015 03:07

Bellingham police: Robber arrested after threatening guard with syringe
HeraldNet - Thu, 28 May 2015 03:07

Hepatitis C treatment may be cost-effective in prisons in England
Reducing the duration of direct-acting antiviral treatment for hepatitis C will make treatment for people in prison in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people ...
aidsmap - Thu, 28 May 2015 15:52

Lawmakers debate mandatory Hep C testing
ILLINOIS -- If you were born between 1945 - 1965, doctors say you're at a higher risk for hepatitis C. The CDC says more than three million people in the U.S. have been diagnosed with the disease. Now, some state lawmakers are trying to make sure you ...
IllinoisHomePage.net - Thu, 28 May 2015 15:30

Baby Boomers: Get Tested for Hepatitis C
AIDS.gov blog (blog) - Thu, 28 May 2015 09:10

Merck files all-oral hepatitis C therapy in US
Merck and Co - US headquarters Merck & Co has submitted its single-tablet combination therapy for hepatitis C virus (HCV) to the US FDA as it tries to catch up with the leading players in the all-oral therapy sector. Merck - known as MSD outside the US ...
PMLiVE - Fri, 29 May 2015 03:18

Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie
FierceBiotech - Fri, 29 May 2015 05:22

Merck Submits New Drug Application for Hepatitis Combination to FDA
Wall Street Journal - Thu, 28 May 2015 14:33

Merck Files New Drug Application for Hepatitis Combination
Nasdaq - Thu, 28 May 2015 14:33

Merck Submits US New Drug Application ...
The FINANCIAL - Thu, 28 May 2015 23:33

Minnesota prison inmates sue to gain access to costly hepatitis C medications
Breakthrough medicine for hepatitis C started being approved in the United States in late 2013, the lawsuit states, and has become the standard of care with a 95 percent cure rate. Yet the inmates have been denied access “in deliberate indifference to ...
Minneapolis Star Tribune - Tue, 26 May 2015 21:58

2 inmates sue state over hepatitis C treatment
Washington Times - Wed, 27 May 2015 04:15

Minn. inmates sue to gain access to costly hepatitis C medications
CorrectionsOne - Wed, 27 May 2015 14:56

Achillion partners with Janssen to boost hepatitis C pipeline
Specialist pharmaceutical firm Achillion is partnering with Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals to develop new hepatitis C drugs. The goal is to add to the latest crop of blockbuster hepatitis C drugs with medicines that require ...
Royal Society of Chemistry - Fri, 29 May 2015 03:07

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014